Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD
Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD
Background: we investigated the use of type 2 diabetes (T2D) medications, including pioglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, in individuals with T2D and metabolic dysfunction–associated steatotic liver disease (MASLD), and explored the effect of these medications on long-term risk of liver-related events (LREs) and progression of liver stiffness in a retrospective cohort study.
Methods: we enrolled 7867 individuals with T2D and MASLD from 16 tertiary referral centers between February 2004 and January 2023. We recorded the use of pioglitazone, GLP-1RAs, and SGLT-2 inhibitors and analyzed the effects of these antihyperglycemic medications on the risk of developing incident LREs and the progression of liver stiffness over a median of 5.1 years of follow-up.
Results: pioglitazone, GLP-1RAs and SGLT-2 inhibitors were prescribed to 1238 (15.7%), 863 (11.0%), and 2386 (30.3%) individuals with T2D and MASLD, respectively. A significant increase in the utilization of GLP-1RAs and SGLT-2 inhibitors was observed from 2010–2017 to 2017–2023, with pioglitazone and SGLT-2 inhibitors being prescribed more frequently in Asian countries than in Western countries (pioglitazone: 17.9% vs 3.8%; SGLT-2 inhibitors: 34.4% vs 7.3%; P < .001). After propensity score matching, in competing risk models, SGLT-2 inhibitor use was significantly associated with a lower risk of developing both LREs (subdistribution hazard ratio, 0.23; 95% confidence interval, 0.08–0.69, P = .009) and liver stiffness progression (hazard ratio, 0.54; 95% confidence interval, 0.35–0.86, P = .008) after adjusting for potential confounders.
Conclusions: SGLT-2 inhibitor use is more prevalent among Asian than Western individuals. SGLT-2 inhibitors are associated with a lower risk of LREs in individuals with T2D and MASLD.
Shi, Yu
eed61b06-3d0a-4cdc-a0fb-9ad6687c36df
Kim, Seung Up
a59d694a-163b-49e5-813e-8b64b4e46c56
Yip, Terry Cheuk-Fung
8f458b7d-01fd-40bc-be0d-17ff74fd8fde
Tsochatzis, Emmanuel
e6463ccf-1f18-45c2-bed5-1e463df255ce
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
VCTE-Prognosis Study Group
Shi, Yu
eed61b06-3d0a-4cdc-a0fb-9ad6687c36df
Kim, Seung Up
a59d694a-163b-49e5-813e-8b64b4e46c56
Yip, Terry Cheuk-Fung
8f458b7d-01fd-40bc-be0d-17ff74fd8fde
Tsochatzis, Emmanuel
e6463ccf-1f18-45c2-bed5-1e463df255ce
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Shi, Yu, Kim, Seung Up, Yip, Terry Cheuk-Fung and Tsochatzis, Emmanuel
,
VCTE-Prognosis Study Group and et al.
(2025)
Effect of antidiabetic drug classes on the risk of liver-related events in individuals with T2D and MASLD.
Clinical Gastroenterology and Hepatology.
(doi:10.1016/j.cgh.2025.06.001).
Abstract
Background: we investigated the use of type 2 diabetes (T2D) medications, including pioglitazone, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, in individuals with T2D and metabolic dysfunction–associated steatotic liver disease (MASLD), and explored the effect of these medications on long-term risk of liver-related events (LREs) and progression of liver stiffness in a retrospective cohort study.
Methods: we enrolled 7867 individuals with T2D and MASLD from 16 tertiary referral centers between February 2004 and January 2023. We recorded the use of pioglitazone, GLP-1RAs, and SGLT-2 inhibitors and analyzed the effects of these antihyperglycemic medications on the risk of developing incident LREs and the progression of liver stiffness over a median of 5.1 years of follow-up.
Results: pioglitazone, GLP-1RAs and SGLT-2 inhibitors were prescribed to 1238 (15.7%), 863 (11.0%), and 2386 (30.3%) individuals with T2D and MASLD, respectively. A significant increase in the utilization of GLP-1RAs and SGLT-2 inhibitors was observed from 2010–2017 to 2017–2023, with pioglitazone and SGLT-2 inhibitors being prescribed more frequently in Asian countries than in Western countries (pioglitazone: 17.9% vs 3.8%; SGLT-2 inhibitors: 34.4% vs 7.3%; P < .001). After propensity score matching, in competing risk models, SGLT-2 inhibitor use was significantly associated with a lower risk of developing both LREs (subdistribution hazard ratio, 0.23; 95% confidence interval, 0.08–0.69, P = .009) and liver stiffness progression (hazard ratio, 0.54; 95% confidence interval, 0.35–0.86, P = .008) after adjusting for potential confounders.
Conclusions: SGLT-2 inhibitor use is more prevalent among Asian than Western individuals. SGLT-2 inhibitors are associated with a lower risk of LREs in individuals with T2D and MASLD.
Text
Revised_Main Text
- Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Revised_Supplemtary information
- Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Figure 1
- Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Figure 2
- Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Figure 3
- Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Text
Revised_graphical abstract
- Accepted Manuscript
Restricted to Repository staff only until 7 June 2026.
Request a copy
Show all 6 downloads.
More information
Accepted/In Press date: 7 June 2025
e-pub ahead of print date: 7 June 2025
Identifiers
Local EPrints ID: 505500
URI: http://eprints.soton.ac.uk/id/eprint/505500
ISSN: 1542-3565
PURE UUID: af5a35fe-5109-48f8-b14a-36de5124ab2c
Catalogue record
Date deposited: 10 Oct 2025 16:38
Last modified: 11 Oct 2025 01:40
Export record
Altmetrics
Contributors
Author:
Yu Shi
Author:
Seung Up Kim
Author:
Terry Cheuk-Fung Yip
Author:
Emmanuel Tsochatzis
Corporate Author: VCTE-Prognosis Study Group
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics